Multiple Sclerosis Relapsing Remitting Progressive Type by Fitri, Nora et al.
                                          Jurnal Profesi Medika : Jurnal Kedokteran dan                             




Vol. 14 No 1 2020 DOI :  http://dx.doi.org/10.33533/jpm.v14i2.2208  199 
 
 
MULTIPLE SCLEROSIS RELAPSING REMITTING PROGRESSIVE TYPE 
 
Nora Fitri1*, Basjiruddin Ahmad2, Yuliarni Syafrita2 
 
1 Faculty of Medical,University of Andalas, Padang, Indonesia 
2 Faculty of Medical, University of Andalas Universitas Andalas / Dr. M. Djamil General Public Hospital, 
Padang, Indonesia  
 





Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income 
countries. The causes of MS are multifactorial involve genetics and the environment in which immune 
cell infiltration occurs across the blood-brain barrier, causing inflammation, demyelination, gliosis, 
and neuroaxonal degeneration substantia grisea in the central nervous system. A 23-year-old female 
patient was treated with four limbs weakened since two weeks ago accompanied by blurred vision, 
pain, cramps, and stiffness in the back muscles and legs. The patient has experienced the same 
complaint before. Clinical findings reveal lhermitte signs, atrophy papillae, and tetraparesis. On 
thoracic vertebral MRI examination without contrast and brain MRI with contrast obtained multiple 
sclerosis lesions. Patients receive steroid and antidepressant therapy. MS needs to be studied further 
because this number of cases began to emerge. 
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INTRODUCTION 
Multiple sclerosis (MS) is the most 
common neurological demyelinating disease 
in high-income countries. The median global 
prevalence of MS increased from 30 per 
100,000 in 2008 to 33 per 100,000 in 2013.1 
Multiple sclerosis is caused by infiltration of 
immune cells across the blood-brain barrier, 
causing inflammation, demyelination, gliosis, 
and neuroaxonal degeneration of the grisea 
substantial of the central nervous system 
(CNS).2 Causes of MS are multifactorial, 
involving both genetics and the environment. 
The gene most strongly associated with MS is 
the HLA-DRB1 * 1501 MHC class II 
haplotype linked to immune function.3,4,5 
Additionally, MS has been linked to vitamin 
D deficiency, connected to several other 
autoimmune diseases.3.6 
CASE PRESENTATION 
A twenty-three-year-old woman was 
treated at the neurology department of RSUD 
M. Djamil with weak four limbs since two 
weeks ago. These conditions had occurred 
gradually since one year ago, where 
conditions began with weakness in both legs. 
These conditions were followed by weakness 
in both arms, which was felt two weeks later. 
The weakness started in the left arm, followed 
by the right arm. Since two weeks ago, she 
only could move his toes and often let go of 
holding objects. These conditions 
accompanied by blurred vision since one 
week ago. Pain, cramps, stiffness in the back 
and legs muscles, and irritability and anger 
have often occurred for one year. For two 
months, the patient has also had a catheter 
attached. 
She had experienced the same 
complaint in 2016, 2017, and January 2018. 
A history of blurred vision also occurred 2x 
in June 2017 and September 2017. In 
December 2017, an MRI of thoracic vertebra 
without contrast was performed where 
multiple tubular-shaped lesions were seen in 
the spinal cord as high as Th3- Th6 with 
transverse myelitis impression (Figure 1). 
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Figure 1. MRI of Thoracal Vertebra without 
contrast (December 2017) 
 
In January 2018, lumbar puncture was 
performed with macroscopic smooth flow, 
clear color, none +1, pandy +1, and 
microscopic cell count of 1 / mm3, CSF 
glucose 91 mgs / dl, blood glucose 195 mgs / 
dl, and protein 800 mgs / l . Contrast brain 
MRI was performed with results within 
normal limits. In February 2018, an MRI of 
the thoracic vertebrae without contrast was 
performed, showing a small size cystic spinal 
cord dilatation with hydrosyringomyelia as 
high as C1-Th12 and susp. Multiple sclerosis 
at the level of Th1-2 and Th4-5 (Figure 2). 
The neurosurgeon performed a drain with an 
indication of hydrosyringomyelia. After the 
operation, the patient can stand by holding the 
wall. 
Physical examination showed a 
moderate general condition, cooperative 
composition with blood pressure (BP) 110/70 
mmHg, pulse 108 x/minute. Lhermitte's sign 
was found, and on funduscopy, the 
impression of papillae atrophy of the right  
and left ocular. Visus OD 1/300 and OS 1 / ∞. 
Superior motor strength 344/443 and inferior 
111/111. Sensory hyperesthesia is found at 
the level of the C5 dermatome and below. 
Urinary retention and sweat secretion are 
impaired at the level of C5-6 dermatome and 
below. Physiological and pathological 
reflexes are increased. Laboratory test when 
she was admitted showed anemia (Hb = 9.8 g 
/ dl (normal level = 12-14 g / dl)) and mild  
hypokalemia (K = 3.3 mmol / L (normal level 
= 3.5-5.1 Mmol / L)) 
Based on clinical findings, physical 
examination, and investigations, the patient 
was diagnosed with relapsing-remitting 
multiple sclerosis (RRMS). During 
hospitalization, patients received  
methylprednisolone 4 x 250 mgs (iv), 
ranitidine 2x 50 mgs (iv), ibuprofen 2 x 400 
mgs (oral) and fluoxetin 1 x 10 mgs (oral). 
She showed clinical improvement in the form 
of improvement in limb weakness and 
improvement in vision. During treatment, the 
patient also received gabapentin 2 x 300 mgs 
(oral) to reduce pain, cramps, and stiffness in 


















Figure 2. MRI of the Thoracal Vertebra 
without contrast (February 2018) 
At the time of treatment, a brain MRI 
was performed in contrast to the results 
showing multiple hyperdense lesions in the 
left lateral paraventricle and left parietal lobe 
(on T2, Flair, and DWI), the lesion did not 
enhance post contrast administration with 
multiple sclerosis impressions. 
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Figure 3. Brain MRI with contrast with 
multiple sclerosis impression (December 
27th, 2018) 
 
The patient went home with motor 
strength 344/222 and vision 1/60 ODS and 
was given 2x300 mgs gabapentin, 2x400 mgs 




Multiple sclerosis (MS) is an 
autoimmune disease, which rarely occurs. 
Because of this rarity, MS is a diagnostic 
challenge in itself. MS is usually diagnosed 
between the ages of 20 and 40 and twice as 
many women as men.2,7,8 Cause of MS is 
multifactorial, combining genetic and 
environmental factors. However, MS's cause 
remains largely unknown.1 Pathological 
feature of MS is that it is characterized by 
involving the brain, spinal cord, and optic 
nerve. Focal lesions are thought to be caused 
by immune cells' infiltration, including T 
cells, B cells, and myeloid cells, into the 
parenchymal of CNS where the injury is 
located.8,9 
This patient's clinical features are visual 
disturbances (optical neuritis), weakness of all 
four limbs (myelitis), pain, cramps, stiffness 
in muscles and joints, and phases of relapse 
and remission. The MS course can be relapse-
remission or progressive but usually involves 
multi-phases and multi-focal (disseminated in 
time and location). Where reversible episodes 
of neurologic deficit last for several days to 
weeks characterize the early stages of the 
disease. Over time, clinical and cognitive 
deficits develop become irreversible. A 
minority of patients have a progressive course 
of the disease from baseline.8,9 
The clinical features of myelitis in MS 
are usually asymmetrical, progressive over 
hours to days, and usually, there is spinter 
involvement.2,7 Optic neuritis may be acute or 
subacute with bilateral or unilateral visual 
impairment, sometimes accompanied by 
retroorbital or ocular pain that worsens with 
eye movement. There is usually a complete or 
partial improvement in the patient.2 
Apart from physical complaints, these 
patients also tend to be more sensitive and 
easily irritated and tired. Mood changes that 
occur in MS, including depression (50%), 
euphoria, and psychosis. Fatigue is common 
in MS patients, where it reaches 84%. Various 
forms of fatigue can occur due to MS disease 
or caused by related factors such as 
depression, lack of sleep due to nocturia or 
seizures, poor appetite.10 Depression in MS 
may involve cytokines that are essential 
components of immune activation during 
inflammation and are involved in an 
oligodendrocyte injury, axonal degeneration, 
and neuronal dysfunction, significant MS 
pathology features. Cytokines are molecules 
produced by immunocompetent cells that 
mediate and coordinate communication 
between cells of the immune system.8 
Pain, cramps, and stiffness in joints and 
muscles also occur in these patients. Impaired 
muscle function in MS patients can manifest 
in involuntary muscle stiffness or movement 
and limited muscle function capacity, which 
focuses on spasticity, spasms, and weakness. 
The primary mechanism of spasticity is the 
hyperexcitability of α motor neurons caused 
by decreased secondary descending inhibitory 
signals that damage of CNS.11  
Lack of inhibition of the 
oligointramedular pathway in the brain or 
polysynaptic in the spinal cord, 
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physiologically mediated by the 
neurotransmitter γ-aminobutyric acid 
(GABA), results in reflex hyperactivity. 
Symptoms include muscle stiffness and/or 
spasms, pain or discomfort, loss of function in 
the upper / lower extremities, and difficulty 
maintaining a standing or sitting posture with 
excessive reflexes, clonus, seizures. 
Spasticity increases with stress and harmful 
stimuli (e.g., pain, pressure, urinary tract 
infections, and usually shows spontaneous 
fluctuations (usually increases at night).11 
Imaging examination that must be done 
to establish MS is MRI. Besides, evoked 
potential (EP) can also be performed, 
especially visual evoked potential (VEP) and 
CSF examination. On MRI examination, you 
will see a Disseminated Lesion in Space (DIS) 
image on the T2 section at least 2 out of 4 
areas, including periventricular, juxtacortical, 
infratentorial, and spinal cord.12 
EP examination aims to measure the 
electrical activity of the brain against stimuli 
in specific sensory nerve pathways. EP can 
detect a decrease in electrical conduction 
caused by damage due to demyelination along 
a pathway. However, the degree of damage is 
so small that it is not visible on clinical 
examination.12 
CSF examination is performed to help 
determine MS's diagnosis and rule out other 
possible diagnoses, especially intracranial 
infections. In CSF, an increase in the 
immunoglobulin G (IgG) index will be 
obtained, or the discovery of ≥ 2 oligoclonal 
bands (OCB), indicating a demyelination 
process due to inflammation. IgG and OCB 
tests have high sensitivity but are not specific 
for MS. OCB can also be found in other 
diseases such as SLE, paraneoplastic 
syndrome, neurosarcoidosis, meningitis, 
neurosyphilis, intracranial masses, vascular 
lesions, and hereditary neurological 
diseases.12 The more important CSF message 
is to rule out other possible diagnoses. The 
high incidence of infection in Indonesia 
requires considering the possibility of 
infection before establishing a diagnosis of 
MS.  
The MS diagnosis was confirmed by the 
revised McDonald Criteria of the 
International Panel on the Diagnosis of MS 
(Table 1). She had ≥ two attacks; there is 
clinical evidence, so it does not require 
additional data to make a diagnosis. MS is 
divided into several types based on the course 
of the disease in the form of relapsing-
remitting MS (RRMS), secondary progressive 
MS (SPMS), primary progressive MS 
(PPMS), progressive relapsing MS (PRMS), 
and benign MS (Table 2).12 She was admitted 
to the RRMS type. 
MRI examination of the spinal cord in 
MS very rarely extends beyond two vertebral 
segments. Generally, the lesions are short, 
asymmetrical, and located in the spinal cord 
section's posterior segment.12 
At the time of complaint of relapse, the 
patient received high intravenous doses of 
methylprednisolone therapy. Treatment in 
MS is divided into therapy at relapse and 
long-term therapy. They are using 
corticosteroids, intravenous immunoglobulin 
(IVIG), or plasma exchange at the time of 
relapse. Glucocorticoids in the form of IV or 
oral methylprednisolone at a dose of 0.5-1 g 
per day for 3-5 days. Long-term therapy in the 
first line uses interferon-β, glatiramer acetate, 
and fingolimod, while in the second line using 
mitoxantrone, natalizumab.13,14,12  
In addition, we can also use 
immunosuppressants mycophenolate mofetil 
(MMF), azathioprine, methotrexate, and 
cyclophosphamide. But its effectiveness still 
needs further study. Studies show that 55% of 
patients do not experience any worsening of 
the condition with cyclophosphamide 
therapy. Other studies have shown the same 
effect of both azathioprine and MMF. Further 
research is needed about the effectiveness of 
immunosuppressants in MS.2,14 
Apart from immunomodulation and 
immunosuppressive therapy, symptom-
specific therapy is an important component of 
MS patients' comprehensive management. 
This therapy aims to reduce complaints that 
can lead to impaired functional ability and 
quality of life. She received phenytoin, 
gabapentin, and pregabalin therapy to reduce 
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spasticity and pain. To reduce spasticity can 
use diazepam 5-30 mgs/day, gabapentin 300-
3600 mgs/day, tizanidine 2-4 mgs/day or 
baclofen 10-120 mgs/day.2,11,14 To reduce 
pain in joints and muscles then can use 
amitriptyline 25-150 mgs/day, gabapentin 
200-1600 mgs/day, 200-400 mgs/day 
lamotrigine or 150-600 mgs/day 
pregabalin.2,14,15 To overcome fatigue in these 
patients, can use amantadine, modafinil , 
pamoline.16 
Depression can be viewed as a clinical 
symptom and a complication of MS, so the 
management of depression is an integral part 
of general MS management. To treat 
depression in these patients, fluoxetin 1x10 
mgs was used. The approach to treating 
depression in MS patients can be carried out 
in three approaches, namely (1) by trying and 
minimizing side effects and potential drug 
interactions such as escitalopram and 
sertraline, which are serotonin selective 
reuptake inhibitors (SSRIs) that have a 
relatively low side effect load and little or no 
significant risk for drug interactions. SSRIs 
do not have significant anticholinergic effects 
(sedation, dry mouth, constipation, indecisive 
urination), antihistaminergics (sedation, 
weight gain), or antiadrenergic (orthostatic 
hypotension). (2) antidepressants whose side 
effects reduce MS symptoms other than 
depressive symptoms such as bupropion, 
fluoxetine, and venlafaxine, which actively 
improve fatigue symptoms in MS or 
desipramine, mirtazapine, and paroxetine are 
sedation and stimulate the patient's appetite, 
which is useful for people with insomnia and 
loss. appetite. (3) antidepressants that are 
useful in simultaneously treating MS 
depression and also help treat comorbid 
conditions apart from depression in the form 
of tricyclic antidepressants (such as 
nortriptyline and desipramine) can help 
incontinence (because they are 
anticholinergic) as well as treat neuropathic 
pain or duloxetine, which are also effective in 
treating pain. Neuropathy or bupropion is 
indicated for the treatment of smoking and 
depression.16 
Multiple sclerosis (MS) is an 
inflammatory disease of the CNS that results 
in progressive neurological regeneration and 
neurological disability. MS most commonly 
affects young adults, especially women. 
Many cases of MS are starting to emerge 
along with the improvement of supporting 
tools such as imaging that complement the 
clinical findings of MS patients so that the 
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